Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Seattle Genetics Inc (SGEN)

Seattle Genetics Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,115,882
  • Shares Outstanding, K 173,997
  • Annual Sales, $ 916,710 K
  • Annual Income, $ -158,650 K
  • 60-Month Beta 1.26
  • Price/Sales 34.34
  • Price/Cash Flow N/A
  • Price/Book 17.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.53
  • Number of Estimates 9
  • High Estimate -0.29
  • Low Estimate -0.65
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +1.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
143.61 +26.70%
on 09/04/20
182.36 -0.22%
on 09/22/20
+24.45 (+15.52%)
since 08/21/20
3-Month
143.61 +26.70%
on 09/04/20
187.99 -3.21%
on 07/20/20
+11.03 (+6.45%)
since 06/22/20
52-Week
72.27 +151.76%
on 09/26/19
187.99 -3.21%
on 07/20/20
+107.94 (+145.85%)
since 09/20/19

Most Recent Stories

More News
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

--- Biologics License Application Submission Planned to Support Accelerated Approval Pathway with the FDA -

SGEN : 181.95 (+1.74%)
GMAB : 38.20 (-0.91%)
Seattle Genetics' Padcev Study Aids Urothelial Cancer Survival

Seattle Genetics' (SGEN) phase III EV-301 study on Padcev meets the main goal of overall survival compared to chemotherapy in patients previously treated for locally advanced/metastatic urothelial cancer....

MRK : 82.94 (-0.23%)
EBS : 100.75 (+0.75%)
SGEN : 181.95 (+1.74%)
HZNP : 78.16 (-0.86%)
Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals

AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.

REGN : 571.51 (+2.85%)
SNY : 49.86 (-1.95%)
AZN : 55.44 (-0.84%)
PFE : 36.25 (+0.64%)
MRK : 82.94 (-0.23%)
LLY : 149.86 (-0.87%)
SGEN : 181.95 (+1.74%)
Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

and , /PRNewswire/ --  (TSE: 4503, President and CEO: , Ph.D., "Astellas") and . (Nasdaq:SGEN) today announced that a phase 3 trial of PADCEV (enfortumab vedotin-ejfv) met its primary endpoint of overall...

ALPMF : 15.0110 (-3.15%)
SGEN : 181.95 (+1.74%)
Seattle Genetics and Astellas Announce PADCEV(R) (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

--- Data Intended to Support Global Registrations and Convert Accelerated to Regular Approval in U.S. -

SGEN : 181.95 (+1.74%)
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More

The biotech sector remains in focus with regulatory and other pipeline updates.

REGN : 571.51 (+2.85%)
GILD : 63.40 (-1.26%)
IMMU : 85.05 (-0.42%)
STSA : 4.33 (-1.37%)
SGEN : 181.95 (+1.74%)
MRNS : 3.14 (-2.18%)
VXRT : 8.75 (-2.67%)
Seattle Genetics Up on Two New Oncology Deals With Merck

Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.

RHHBY : 46.3100 (+0.02%)
MRK : 82.94 (-0.23%)
EBS : 100.75 (+0.75%)
SGEN : 181.95 (+1.74%)
Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug

Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East...

RHHBY : 46.3100 (+0.02%)
GILD : 63.40 (-1.26%)
MRK : 82.94 (-0.23%)
SGEN : 181.95 (+1.74%)
Stock Market News for Sep 15, 2020

U.S. stock markets closed higher on Monday reversing some of the losses of the last week.

NVDA : 505.51 (+0.96%)
AZN : 55.44 (-0.84%)
PFE : 36.25 (+0.64%)
GILD : 63.40 (-1.26%)
MRK : 82.94 (-0.23%)
INCY : 86.93 (+1.80%)
LLY : 149.86 (-0.87%)
IMMU : 85.05 (-0.42%)
SGEN : 181.95 (+1.74%)
BNTX : 67.05 (+1.41%)
Scientific Games; Nvidia rise; Marathon Oil, Hologic fall

NEW YORK (AP) — Stocks that moved heavily or traded substantially Monday:

NVDA : 505.51 (+0.96%)
SGEN : 181.95 (+1.74%)
IMMU : 85.05 (-0.42%)
MRO : 4.47 (-1.97%)
HOLX : 65.38 (+0.40%)
PFE : 36.25 (+0.64%)
SGMS : 33.77 (-0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade SGEN with:

Business Summary

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability...

See More

Key Turning Points

2nd Resistance Point 185.60
1st Resistance Point 183.77
Last Price 181.95
1st Support Level 178.71
2nd Support Level 175.48

See More

52-Week High 187.99
Last Price 181.95
Fibonacci 61.8% 143.78
Fibonacci 50% 130.13
Fibonacci 38.2% 116.47
52-Week Low 72.27

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar